- Home
- DYAI vs ATRA Comparison
DYAI vs ATRA Comparison
Compare DYAI & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | ATRA |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 38.9M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DYAI | ATRA |
|---|---|---|
| Price | $1.00 | $8.45 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 220.4K | 59.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | $3,090,345.00 | ★ $120,772,000.00 |
| Revenue This Year | $122.79 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $3.92 |
| 52 Week High | $1.60 | $19.15 |
Technical Indicators
Market Signals| Indicator | DYAI | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 43.46 |
| Support Level | $0.76 | $7.65 |
| Resistance Level | $1.21 | $11.17 |
| Average True Range (ATR) | 0.16 | 0.59 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 10.77 | 50.00 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).